Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sirolimus albumin bound - Abraxis Bioscience

Drug Profile

Sirolimus albumin bound - Abraxis Bioscience

Alternative Names: ABI-009; Nab-rapamycin; Nab-sirolimus

Latest Information Update: 31 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abraxis BioScience
  • Developer AADi; Children's Oncology Group; National Cancer Institute (USA); Seattle Children's Hospital
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Glioma; Perivascular epithelioid cell tumours
  • Phase I/II Bladder cancer; Colorectal cancer; Sarcoma
  • Phase I Epilepsy; Pulmonary arterial hypertension; Solid tumours

Most Recent Events

  • 25 Jan 2019 AADi initiated an expanded access program for Sirolimus albumin bound for advanced malignant Perivascular epithelioid cell tumor (PEComa)(late-stage disease or greater) (NCT03817515)
  • 23 Nov 2018 AADi plans to initiate a phase IIa trial for Leigh disease (In children, In adolescents) in April 2019 (Parenteral) (NCT03747328)
  • 13 Sep 2018 AADi plans a phase II trial for Neuroendocrine tumours (Inoperable/unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (IV), in November 2018 (NCT03670030)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top